Prognostic significance of therapy-induced myelosuppression in newly diagnosed glioblastoma.
anemia
chemoradiotherapy
lymphopenia
neutropenia
progression
survival
temozolomide
thrombocytopenia
Journal
Neuro-oncology
ISSN: 1523-5866
Titre abrégé: Neuro Oncol
Pays: England
ID NLM: 100887420
Informations de publication
Date de publication:
01 09 2022
01 09 2022
Historique:
pubmed:
22
3
2022
medline:
9
9
2022
entrez:
21
3
2022
Statut:
ppublish
Résumé
Myelosuppression is the major toxicity encountered during temozolomide chemoradiotherapy for newly diagnosed glioblastoma. We assessed the association of myelosuppression (neutropenia, thrombocytopenia, anemia, and lymphopenia) during temozolomide chemoradiotherapy alone or in combination with experimental agents with progression-free survival (PFS) or overall survival (OS) in 2073 patients with newly diagnosed glioblastoma enrolled into five clinical trials: CENTRIC, CORE, EORTC 26082, AVAglio, and EORTC 26981. A landmark Cox model was used. For each primary association analysis, a significance level of 1.7% was used. Lower neutrophil counts at baseline were associated with better PFS (P = .011) and OS (P < .001), independently of steroid intake. Females experienced uniformly more myelotoxicity than males. Lymphopenia during concomitant chemoradiotherapy was associated with OS (P = .009): low-grade (1-2) lymphopenia might be associated with superior OS (HR 0.78, 98.3% CI 0.58-1.06), whereas high-grade (3-4) lymphopenia might be associated with inferior OS (HR 1.08, 98.3% CI 0.75-1.54). There were no associations of altered hematological parameters during concomitant chemoradiotherapy with PFS. During maintenance chemoradiotherapy, no significant association was found between any parameter of myelosuppression and PFS or OS, although exploratory analysis at 5% significance level indicated that either mild-to-moderate (HR 0.76, 95% CI 0.62-0.93) or high-grade lymphopenia (HR 0.65, 95% CI 0.46-0.92) was associated with superior OS (P = .013), but not PFS. The association of higher neutrophil counts at baseline with inferior PFS and OS requires further prospective evaluation. The link of therapy-induced lymphopenia to better outcome may guide the design for immunotherapy trials in newly diagnosed glioblastoma.
Sections du résumé
BACKGROUND
Myelosuppression is the major toxicity encountered during temozolomide chemoradiotherapy for newly diagnosed glioblastoma.
METHODS
We assessed the association of myelosuppression (neutropenia, thrombocytopenia, anemia, and lymphopenia) during temozolomide chemoradiotherapy alone or in combination with experimental agents with progression-free survival (PFS) or overall survival (OS) in 2073 patients with newly diagnosed glioblastoma enrolled into five clinical trials: CENTRIC, CORE, EORTC 26082, AVAglio, and EORTC 26981. A landmark Cox model was used. For each primary association analysis, a significance level of 1.7% was used.
RESULTS
Lower neutrophil counts at baseline were associated with better PFS (P = .011) and OS (P < .001), independently of steroid intake. Females experienced uniformly more myelotoxicity than males. Lymphopenia during concomitant chemoradiotherapy was associated with OS (P = .009): low-grade (1-2) lymphopenia might be associated with superior OS (HR 0.78, 98.3% CI 0.58-1.06), whereas high-grade (3-4) lymphopenia might be associated with inferior OS (HR 1.08, 98.3% CI 0.75-1.54). There were no associations of altered hematological parameters during concomitant chemoradiotherapy with PFS. During maintenance chemoradiotherapy, no significant association was found between any parameter of myelosuppression and PFS or OS, although exploratory analysis at 5% significance level indicated that either mild-to-moderate (HR 0.76, 95% CI 0.62-0.93) or high-grade lymphopenia (HR 0.65, 95% CI 0.46-0.92) was associated with superior OS (P = .013), but not PFS.
CONCLUSIONS
The association of higher neutrophil counts at baseline with inferior PFS and OS requires further prospective evaluation. The link of therapy-induced lymphopenia to better outcome may guide the design for immunotherapy trials in newly diagnosed glioblastoma.
Identifiants
pubmed: 35312789
pii: 6551573
doi: 10.1093/neuonc/noac070
pmc: PMC9435483
doi:
Substances chimiques
Antineoplastic Agents, Alkylating
0
Temozolomide
YF1K15M17Y
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1533-1545Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
Neuro Oncol. 2015 May;17(5):708-17
pubmed: 25762461
Brain. 2016 May;139(Pt 5):1458-71
pubmed: 27020328
Clin Cancer Res. 2016 Oct 1;22(19):4797-4806
pubmed: 27143690
Clin Transl Radiat Oncol. 2018 Apr 13;10:47-52
pubmed: 29928705
N Engl J Med. 2005 Mar 10;352(10):997-1003
pubmed: 15758010
Lancet Oncol. 2009 May;10(5):459-66
pubmed: 19269895
Neurosurg Rev. 2018 Apr;41(2):621-628
pubmed: 28887717
Am J Clin Oncol. 2015 Oct;38(5):514-9
pubmed: 24064758
Neuro Oncol. 2020 Aug 17;22(8):1073-1113
pubmed: 32328653
J Nucl Cardiol. 2019 Apr;26(2):391-393
pubmed: 30719655
Front Neurol. 2020 Oct 07;11:580101
pubmed: 33117267
J Neurooncol. 2017 May;132(3):463-471
pubmed: 28332000
Neurology. 2019 Nov 5;93(19):e1799-e1806
pubmed: 31586022
Nat Rev Clin Oncol. 2021 Mar;18(3):170-186
pubmed: 33293629
Oncoimmunology. 2013 Feb 1;2(2):e23288
pubmed: 23525955
J Neurooncol. 2021 Jan;151(1):55-62
pubmed: 32813186
Stat Biosci. 2017;9(2):489-503
pubmed: 29225713
J Neurosurg. 2017 Jul;127(1):132-138
pubmed: 27739940
J Clin Oncol. 2004 Feb 15;22(4):610-6
pubmed: 14726505
Neuro Oncol. 2011 Mar;13(3):324-33
pubmed: 21149254
Neuro Oncol. 2009 Dec;11(6):825-32
pubmed: 19179423
Clin Cancer Res. 2011 Aug 15;17(16):5473-80
pubmed: 21737504
Lancet Oncol. 2014 Sep;15(10):1100-8
pubmed: 25163906
J Natl Compr Canc Netw. 2015 Oct;13(10):1225-31
pubmed: 26483062
Neuro Oncol. 2007 Jan;9(1):47-52
pubmed: 17108062
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
N Engl J Med. 2014 Feb 20;370(8):709-22
pubmed: 24552318